Are growing EU pharmaceutical powers a threat independence of devices sector?
This article was originally published in Clinica
Executive Summary
Just as the Global Harmonization Task Force was holding its 11th meeting in Washington, DC, to look at how to promulgate standard medical device regulations globally, EU device industry experts were convening in Copenhagen Denmark, where concerns over the overlap area with pharma revealed a threat to the very independence of the devices sector. Amanda Maxwell reports
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.